Objectives This study aimed to assess the effects of incorporating Kinesio-taping (KT) into a chest physical therapy program on alleviating pain and enhancing pulmonary function, respiratory muscle strength, and quality of life following mastectomy. Design This was a prospective, randomized controlled trial. Setting Physiotherapy outpatient clinic. Participants Sixty participants aged 30–50 years who had undergone modified radical mastectomy were randomly allocated to either the Kinesio-taping or traditional physical therapy exercise group. Intervention The Kinesio-taping group received both Kinesio-taping and traditional chest physiotherapy. The control group received only the traditional chest physiotherapy program. The interventions were administered over a 4-week period. Outcome measures The primary outcome measure was pain, which was evaluated using a visual analogue scale (VAS). Secondary outcomes included pulmonary function, specifically forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), assessed via spirometry; respiratory muscle strength, determined by measuring maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) using a portable pressure device; and quality of life, assessed using the Short Form-36 (SF-36) questionnaire. All outcomes were measured at baseline and 4 weeks after the intervention. Results The evaluated parameters exhibited significant alterations between the pre- and post-intervention after a duration of 4 weeks in both groups. The results indicated a significant changes ( p < 0.001) in post-intervention measures compared to pre-intervention measures in both groups. No significant differences were observed between the groups before the intervention. The KT group demonstrated superior postintervention outcomes. Specifically, the KT group showed a significant reduction in VAS scores post-intervention than the control group (3.97 ± 1.65 vs. 6.50 ± 1.57, p < 0.001). Post-intervention, the KT group exhibited significantly higher values ( p < 0.001) of FVC, FEV1, and FEV1/FVC (3.52 ± 0.64 L, 2.95 ± 0.56 L, and 85.09 ± 12.07%) compared to the control group (2.38 ± 0.56 L, 1.74 ± 0.54 L, and 72.39 ± 10.82%), respectively. Additionally, post-intervention MIP and MEP values were significantly higher ( p < 0.001) in the KT group. Conclusion Integrating Kinesio-taping into a standard chest physiotherapy program significantly reduced pain and enhanced pulmonary function, respiratory muscle strength, and quality of life in post-mastectomy patients compared to the application of traditional chest physiotherapy alone. Clinical trial registration ClinicalTrials.gov , identifier NCT06701591.
= 1.79 ± 0.05 µM), supporting its targeted anti-angiogenic mechanism. Flow cytometry analysis showed that 7e induced G0/G1 cell cycle arrest and markedly increased apoptotic cell populations. This was further confirmed by upregulation of Bax, Caspase-3, and Caspase-8, alongside downregulation of Bcl-2, indicating activation of both intrinsic and extrinsic apoptotic pathways. Interestingly, 7e inhibited cancer cell migration, suggesting a potential anti-angiogenetic effect. Density functional theory (DFT) calculations revealed that 7e possesses a conjugated electronic system with a suitable frontier orbital distribution, moderate HOMO-LUMO gap, and a favorable electrostatic potential for receptor interaction. Molecular docking and dynamics simulations demonstrated stable binding of 7e within the VEGFR-2 active site, supported by consistent RMSD, hydrogen bonding, and compact structural behavior. MM-GBSA calculations confirmed favorable binding free energy, while per-residue decomposition and protein-ligand interaction fingerprint analysis identified key stabilizing interactions. Essential dynamics and free energy landscape mapping further confirmed a stable and energetically favorable conformational state. ADMET and toxicity predictions indicated acceptable pharmacokinetic properties, low mutagenic risk, and an overall favorable safety profile. Collectively, these findings identify compound 7e as a promising VEGFR-2-targeted anticancer lead with strong enzymatic inhibition, potent cytotoxicity, and a well-supported mechanistic profile integrating experimental and computational evidence.
Background: Family physicians evaluate skin disorders associated with diagnostic delay, systemic deterioration, tissue destruction, or delayed cancer treatment. These presentations include suspected malignancy, severe drug reactions, and invasive infection, although their referral pathways differ, this review evaluated diagnostic and referral performance in these categories. Methods: Original studies published through 31 Jan 2026 were reviewed using predefined criteria. Patient-based investigations were separated from studies using standardized photographs or clinical vignettes, while cancer pathways were analyzed independently from same-day dermatologic emergencies. Results: Ten studies evaluated diagnostic classification, referral, excision decisions, or image-based recognition. Melanoma sensitivity in general practitioners was 29% in one comparative study, whereas another reported 66.7% sensitivity and 92.0% specificity for recognizing malignant lesions. Following training, dermoscopy increased referral sensitivity from 54.1% to 79.2% without reducing specificity. Sequential dermoscopy reduced excision or referral of suspicious lesions by 56.4%, whereas other diagnostic aids produced inconsistent effects. In an urgent-disease vignette study, family physicians recognized Stevens-Johnson syndrome in 71.4% and pemphigus vulgaris in 28.6% of responses. Conclusion: Diagnostic performance varied according to disease spectrum, clinical setting, physician experience, assessment method, and outcome definition. Training-supported dermoscopy improved selected cancer-triage outcomes, although benefits were not reproduced across all diagnostic technologies.
ABSTRACT Isatin‐based ligands have been recognized for their remarkable pharmacological potential and this study reports the synthesis, characterization, and biological evaluation of three novel nickel(II)‐isatin hydrazone complexes ( C1–C3 ). The complexes were characterized by FT‐IR, UV–vis, mass spectroscopy, DFT, magnetic, conductivity and thermal analyses indicating octahedral geometry and appreciable heat stability. Molecular electrostatic potential mapping gave information on their electronic properties. DFT calculations indicated decreased HOMO–LUMO gaps indicating increased reactivity. Biological screening showed remarkable anticancer activity against HCT‐116, A549, MCF‐7, and HepG‐2 cell lines (IC 50 = 7.22–17.33 µM), potent antibacterial and antifungal activities comparable to ciprofloxacin and clotrimazole against Staphylococcus aureus and Candida albicans , and significant antioxidant activity with 59%–69% of the radical scavenging. Molecular docking and dynamics studies showed the stable binding interactions with the target enzyme FabH especially for complex C3 . These results collectively highlight C1‐C3 as multifunctional therapeutic candidates with stability and reactivity properties, making them attractive scaffolds for pharmacological development.
Cell Biochemistry and Function · مجلد 44 (10) · e70321-e70321
Patient-derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long-standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three-dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural, genomic, and phenotypic characteristics of their tumors of origin, enabling more accurate modeling of tumor heterogeneity and disease evolution. Over the last decade, rapid methodological advances in organoid culture systems, extracellular matrices (ECMs), and growth factor optimization have facilitated the establishment of organoid models for a wide range of malignancies and the development of large living biobanks representing diverse patient populations. These models are increasingly being utilized to study cancer biology, elucidate mechanisms of treatment resistance, and evaluate patient-specific therapeutic responses, highlighting their potential as tools for precision oncology. However, important challenges remain, including incomplete representation of the tumor microenvironment (TME), variability in culture conditions, and limited scalability, and the need for greater standardization and validation. Consequently, although PDOs show considerable promise for translational research and personalized medicine, their routine clinical implementation remains largely investigational, and their clinical utility has not yet been fully established. This review examines the technological foundations of PDO generation, assesses their role as experimental models of tumor biology, and discusses their expanding applications in translational cancer research and precision oncology while highlighting key challenges that must be addressed before their widespread clinical adoption.
Background Breast cancer is the most prevalent female malignancy in Saudi Arabia and globally, with early detection being the cornerstone of improved survival. This study assesses breast cancer screening awareness, knowledge of risk factors and signs, and screening practices among non-medical female university students in Riyadh, Saudi Arabia. Methods A cross-sectional study (July-September 2025) enrolled 679 non-medical female students aged 18 years and above from four Riyadh universities using multistage sampling. Data were collected using a structured, bilingual 58-item questionnaire adapted from previous studies, culturally modified, pilot-tested, and reviewed by experts. Knowledge and practice domains were classified as sufficient when scores exceeded 60% and insufficient when scores were ≤60%. Knowledge scores were analyzed using Mann-Whitney U and Kruskal-Wallis tests with Bonferroni correction; chi-square tests and multivariate logistic regression identified significant predictors. Results Despite 85% (n = 578) demonstrating sufficient attitudes toward screening, only 44% (n = 299) had adequate general awareness, 19% (n = 132) had sufficient knowledge of risk factors and signs, and 23% (n = 158) achieved sufficient screening practice. The median knowledge score was 19/43 (IQR: 16-22). Family history (65.5%, n = 445) and increasing age (56.7%, n = 385) were the most recognized risk factors, while early puberty (16.2%, n = 110) and nulliparity (23.6%, n = 160) were the least. While 90.9% (n = 617) identified a breast mass as a sign, only 5.9% (n = 40) correctly recognized that a painful mass is not a typical early presentation. Breast self-examination and clinical breast examination uptake were low at 40.4% (n = 274) and 23.4% (n = 159), respectively. However, these screening practice findings should be interpreted considering the young age distribution of participants, with many being below the recommended age for routine mammography screening. AlMaarefa University affiliation was the strongest predictor of knowledge (OR = 2.718; 95% CI: 1.398-5.282; p = 0.003) and screening practice (OR = 5.488; 95% CI: 2.863-10.519; p < 0.001), with family history also predicting sufficient screening practice (OR = 2.384; 95% CI: 1.488-3.819; p < 0.001). Conclusion A striking knowledge-attitude-practice gap exists in this population. Universities are underutilized platforms for breast cancer health education, and structured, culturally sensitive interventions are urgently needed to convert attitudinal willingness into consistent screening practice.
breast cancer screeningknowledge-practice gapfemale university studentsbreast cancer risk factors
Background/Objectives: Repurposing existing drugs may represent a promising strategy for effective cancer therapy. This study was the first to investigate the augmented antitumor therapeutic effect achieved by co-incorporating the NSAID Niflumic acid (NIF) with ceramides into PEGylated cerosomes (NIF-loaded PEG-CERs) in a novel platform that targets specifically the MAPK-ERK signaling pathway and miR-21-5p modulation. Methods: The prepared formulae were statistically optimized utilizing a full factorial design and the optimal formula (C5) was further incorporated into a topical gel and evaluated for ex vivo rat skin permeation, and tested in vivo in a subcutaneous solid Ehrlich carcinoma (SEC) mice model. Results: The optimal formula (C5) showed tubular elongated morphology with higher EE% (96.71 ± 0.0), lower vesicular size (VS) and PDI values, 292.95 ± 0.78 nm and 0.47 ± 0.0 respectively. A high ZP value (−37.5 ± 0.57 mV) was in accordance with stability results showing good stability of the optimal formula (C5). Permeability studies exhibited 2.02-fold higher skin permeation compared to pure NIF gel. A significant decrease in tumor volume and marked improvement in survival rate in SEC mice were confirmed by downregulation of EGFR, ERK1, ERK2, and miR-21-5p expression. Furthermore, an increase in total antioxidant capacity and caspase-3 levels was observed, accompanied by significant suppression in cyclin D1, MMP-2, COX-2, and MDA levels. Finally, histopathological analysis revealed the superior antitumor effect of C5 gel together with immunohistochemical assay showing the lowest BCL-2-positive staining, indicating the restoration of physiological apoptotic balance. Conclusions: Based on the previous findings, NIF-loaded PEG-CERs offer augmented therapeutic potential for efficient topical skin cancer management in an SEC mice model.
Aims This study aimed to design, synthesize, and evaluate novel benzanilide derivatives as potential anticancer agents targeting VEGFR-2-mediated tumor angiogenesis.Materials and methods Eight benzanilide derivatives (7a-e, 9a-b, and 11) were synthesized and structurally confirmed using spectroscopic methods. The compounds were evaluated via molecular docking, in silico ADMET profiling, in vitro cytotoxicity against MCF-7, MDA-MB-231, HepG-2, and HCT-116 cancer cell lines, and selectivity assessment using WI-38 and WISH normal cell lines. VEGFR-2 enzyme inhibition was also determined for the most active compound.Results Compound 11 exhibited the highest cytotoxic activity with IC50 values of 6.08, 5.76, 7.94, and 4.64 µM against MCF-7, MDA-MB-231, HepG-2, and HCT-116, respectively, comparable to sorafenib. It showed potent VEGFR-2 inhibition (IC50 = 0.414 µM) superior to sorafenib (0.809 µM). Mechanistic studies indicated activation of apoptosis via upregulation of Bax, Caspase-3, and Caspase-8 and downregulation of Bcl-2. ADMET results revealed favorable pharmacokinetic properties and acceptable safety profiles.Conclusions Compound 11 represents a promising VEGFR-2 inhibitor with potent anticancer activity and favorable drug-like properties, warranting further optimization and development.
Archiv der Pharmazie · مجلد 359 (9) · e70328-e70328
ABSTRACT A new series of chromene derivatives ( 12–19 ) was rationally designed as potential inhibitors of vascular endothelial growth factor receptor‐2 (VEGFR‐2) by integrating essential pharmacophoric and structural features. The target compounds were synthesized and structurally confirmed using spectroscopic techniques. Their in vitro antiproliferative activities were evaluated against a panel of human cancer cell lines (MCF‐7, MDA‐MB‐231, HepG‐2, and HCT‐116) alongside normal human cells (WI‐38 and WISH), in addition to a VEGFR‐2 enzyme inhibition assay. Among the synthesized derivatives, compound 17 emerged as the most potent candidate, displaying low micromolar IC 50 values across all tested cancer cell lines and superior VEGFR‐2 inhibitory activity (IC 50 = 0.518 µM) compared with the reference drug sorafenib (IC 50 = 0.809 µM). Mechanistic investigations revealed that compound 17 induced pronounced cell cycle arrest and triggered apoptosis, as demonstrated by Annexin V–FITC/PI flow cytometric analysis. Computationally, Density Functional Theory (DFT) calculations demonstrated favorable electronic properties for compound 17, supporting effective ligand–receptor interactions. Molecular docking and 100‐ns molecular dynamics (MD) simulations, complemented by MM‐GBSA binding free energy calculations, Protein–Ligand Interaction Fingerprinting (Pro‐LIF), Principal Component Analysis (PCA‐T), and Free Energy Landscape (FEL) analyses, confirmed the stability and favorable binding energetics of compound 17 within the VEGFR‐2 active site. Furthermore, in silico ADME–Tox profiling predicted acceptable pharmacokinetic behavior and a favorable safety profile. Collectively, these experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.
Journal of Biomolecular Structure and Dynamics · مجلد 44 (16) · 7537-7551
Targeting the immune checkpoint programmed cell death-ligand 1 (PD-L1) faces diverse challenges against pancreatic ductal adenocarcinoma (PDAC), the most common type of cancer-related death. Shedding of PD-L1 from the tumor cell surface by A Disintegrin And Metalloprotease 10 (ADAM10) may impede the function of antitumor immune cells. Understanding the molecular mechanisms behind this interaction is urgently needed. This study elucidates the mechanism of ADAM10/PD-L1 interaction in the pancreatic adenocarcinoma cell line, PANC-1, using cellular assays, molecular docking, and molecular dynamics (MD) simulations. Cellular assays validated that ADAM10 interacts with PD-L1 and sheds the PD-L1 from the cell surface, generating soluble PD-L1 (sPD-L1). Concurrently, the docking results identified critical residues and potential contact points, providing strong evidence for a stable and specific interaction between ADAM10 and PD-L1. The molecular dynamics (MD) simulations further confirmed the structural integrity of the ADAM10/PD-L1 complex, predicting its compactness and stability. These results elucidate how ADAM10 recognizes and interacts with PD-L1, facilitating its cleavage. Future work can leverage these findings to develop potent cancer immunotherapies that inhibit the ADAM10/PD-L1 interaction and the generation of soluble molecules.
Sultan Qaboos University medical journal · مجلد 26 (1) · 455-465
Objectives: Breast cancer (BC) is the most common malignancy among women worldwide and represents a significant burden for Yemeni women. Early detection through breast self-examination (BSE) and knowledge of risk factors and symptoms are crucial. This study aimed to assess awareness, knowledge and practice regarding BC risk factors, symptoms and BSE among female healthcare workers (HCWs) in Al-Mukalla, Yemen. Methods: This cross-sectional study was conducted from September to October 2022 at three public hospitals in Al-Mukalla, Yemen. A census sampling approach was used to recruit HCWs. Data were collected using a validated self-administered questionnaire covering breast awareness practices, risk factor awareness, symptom recognition and BSE frequency. Descriptive statistics and logistic regression were used to identify BSE predictors. Results: A total of 151 HCWs were included in this study (response rate = 83.0%). The mean participant age was 30.4 ± 6.1 years; 49.7% were aged 20–29 years. Most participants were unmarried (66.2%), university-educated (57.0%) and doctors (47.0%). Knowledge of hallmark symptoms such as breast masses (90.0%) was high; however, 51.0% misidentified the specific laterality (right upper outer quadrant) of the most common cancer site, rather than the quadrant itself. Regular (monthly) BSE was reported by 71.5% of participants. Multivariable analysis showed that nurses were less likely than doctors to perform BSE (adjusted odds ratio [aOR] = 0.32, 95% confidence interval [CI]: 0.14–0.73; P = 0.007). Diploma holders practised BSE less than university graduates (aOR = 0.38, 95% CI: 0.19–0.78; P = 0.008), while higher BC knowledge independently predicted greater BSE practice (aOR = 2.15, 95% CI: 1.10–4.20; P = 0.025). Conclusion: Despite good symptom awareness, significant knowledge gaps remain regarding risk factors and breast anatomy among female HCWs in Al-Mukalla, Yemen. BSE practice is still suboptimal, influenced by professional role, education level and BC knowledge. Targeted interventions focusing on breast awareness and structured education are urgently required.
breast cancerbreast self-examinationbreast cancer screeningbreast cancer knowledge
Journal of Computational Biophysics and Chemistry · 1-20
The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy ([Formula: see text] kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC[Formula: see text]M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2-targeted anticancer lead compound with strong inhibitory potency and a clearly defined mechanism of action, supporting its progression for further improvement.
VEGFR-2 inhibitorsbenzanilidestumor angiogenesisanticancer drug discovery